• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab.

作者信息

Saburi Masuho, Sakata Masanori, Kodama Yousuke, Uraisami Keiichi, Takata Hiroyuki, Miyazaki Yasuhiko, Wada Junpei, Urabe Shogo, Ohtsuka Eiichi

机构信息

Department of Hematology, Oita Prefectural Hospital, Oita, Japan.

Department of Pathology, Oita Prefectural Hospital, Oita, Japan.

出版信息

J Clin Exp Hematop. 2023 Sep 28;63(3):201-204. doi: 10.3960/jslrt.23017. Epub 2023 Jul 28.

DOI:10.3960/jslrt.23017
PMID:37518271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10628823/
Abstract
摘要

相似文献

1
Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab.复发/难治性伴有MYC易位的弥漫性大B细胞淋巴瘤采用泊洛妥珠单抗、苯达莫司汀和利妥昔单抗治疗的临床结局较差。
J Clin Exp Hematop. 2023 Sep 28;63(3):201-204. doi: 10.3960/jslrt.23017. Epub 2023 Jul 28.
2
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey.波拉珠单抗维地布妥昔单抗、利妥昔单抗和苯达莫司汀联合治疗复发或难治性弥漫性大 B 细胞淋巴瘤：来自土耳其的真实世界数据。
Ann Hematol. 2023 Jan;102(1):133-140. doi: 10.1007/s00277-022-05052-x. Epub 2022 Nov 19.
3
Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.泊洛妥珠单抗联合苯达莫司汀及利妥昔单抗用于治疗复发或难治性弥漫性大B细胞淋巴瘤。
Drugs Today (Barc). 2020 Apr;56(4):287-294. doi: 10.1358/dot.2020.56.4.3127026.
4
Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma.泊洛妥珠单抗联合苯达莫司汀和利妥昔单抗（Pola-BR）对一名难治性弥漫性大B细胞淋巴瘤患者的神经淋巴瘤有效。
Ann Hematol. 2023 Jan;102(1):223-225. doi: 10.1007/s00277-022-05039-8. Epub 2022 Nov 17.
5
Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.塔法西单抗联合来那度胺对比 3 种利妥昔单抗为基础的治疗方案用于不适合移植的复发/难治性弥漫性大 B 细胞淋巴瘤：一项匹配调整的间接比较。
Adv Ther. 2022 Jun;39(6):2668-2687. doi: 10.1007/s12325-022-02094-5. Epub 2022 Apr 11.
6
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.抗 CD79B 抗体药物偶联物 polatuzumab vedotin 在复发或难治性 B 细胞非霍奇金淋巴瘤和慢性淋巴细胞白血病中的安全性和活性：一项 1 期研究。
Lancet Oncol. 2015 Jun;16(6):704-15. doi: 10.1016/S1470-2045(15)70128-2. Epub 2015 Apr 27.
7
[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].泊洛妥珠单抗、苯达莫司汀和利妥昔单抗用于复发/难治性弥漫性大B细胞淋巴瘤患者，包括作为CAR-T细胞疗法或异基因造血干细胞移植的桥接治疗的结果
Rinsho Ketsueki. 2023;64(7):586-595. doi: 10.11406/rinketsu.64.586.
8
[Efficacy and safety of Polatuzumab Vedotin in combination with rituximab plus bendamustine in patients with relapsed/refractory diffuse large B-cell lymphoma: a single center analysis].泊洛妥珠单抗联合利妥昔单抗及苯达莫司汀治疗复发/难治性弥漫性大B细胞淋巴瘤患者的疗效和安全性：一项单中心分析
Zhonghua Xue Ye Xue Za Zhi. 2022 Jan 14;43(1):66-69. doi: 10.3760/cma.j.issn.0253-2727.2022.01.013.
9
Polatuzumab vedotin combined with rituximab-bendamustine immediately before stem cell mobilization in relapsed diffuse large B-cell lymphoma.在复发的弥漫性大B细胞淋巴瘤中，在干细胞动员前立即使用泊洛妥珠单抗维达汀联合利妥昔单抗-苯达莫司汀。
Ann Hematol. 2022 Jul;101(7):1609-1610. doi: 10.1007/s00277-022-04803-0. Epub 2022 Feb 26.
10
A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.一项评估泊洛妥珠单抗联合苯达莫司汀和利妥昔单抗治疗复发/难治性弥漫性大 B 细胞淋巴瘤的 2 期研究。
Cancer Sci. 2021 Jul;112(7):2845-2854. doi: 10.1111/cas.14937. Epub 2021 Jun 4.

引用本文的文献

1
A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS).一项基于美国食品药品监督管理局不良事件报告系统（FAERS）的泊洛妥珠单抗维布妥昔单抗真实世界药物警戒研究。
Front Pharmacol. 2024 Jun 25;15:1405023. doi: 10.3389/fphar.2024.1405023. eCollection 2024.

本文引用的文献

1
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL.一项关于泊洛妥珠单抗、苯达莫司汀和利妥昔单抗用于复发/难治性弥漫性大B细胞淋巴瘤的英国真实世界研究结果。
Blood Adv. 2022 May 10;6(9):2920-2926. doi: 10.1182/bloodadvances.2021005953.
2
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.基于泊马度胺的挽救性免疫化疗作为弥漫性大 B 细胞淋巴瘤三线或以上治疗的真实世界经验。
Ann Hematol. 2022 Feb;101(2):349-358. doi: 10.1007/s00277-021-04711-9. Epub 2021 Nov 11.
3
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data.波拉珠单抗维地布汀联合苯达莫司汀和利妥昔单抗治疗复发/难治性弥漫性大 B 细胞淋巴瘤：生存数据更新及新扩展队列数据。
Blood Adv. 2022 Jan 25;6(2):533-543. doi: 10.1182/bloodadvances.2021005794.
4
Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.在侵袭性 B 细胞淋巴瘤中，联用泊马度胺、利妥昔单抗和苯达莫司汀的真实临床经验。
Hematol Oncol. 2021 Aug;39(3):336-348. doi: 10.1002/hon.2842. Epub 2021 Mar 2.
5
Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis.泊洛妥珠单抗治疗复发/难治性侵袭性B细胞淋巴瘤：一项多中心上市后分析。
Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):170-175. doi: 10.1016/j.clml.2020.12.013. Epub 2020 Dec 18.
6
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.西达基奥仑赛治疗复发或难治性大 B 细胞淋巴瘤患者的疗效和安全性（TRANSCEND NHL 001）：一项多中心无缝设计研究。
Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.
7
Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data.泊洛妥珠单抗治疗复发/难治性非霍奇金淋巴瘤患者的概况：关于新出现临床数据的简要报告
Onco Targets Ther. 2020 Jun 8;13:5123-5133. doi: 10.2147/OTT.S219449. eCollection 2020.
8
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
9
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
10
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.霍奇金淋巴瘤和非霍奇金淋巴瘤初始评估、分期及反应评估的建议：卢加诺分类
J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800.